Position in TRVI
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$348,587
+$114,807 QoQ
Shares Held
18,691
-4.6% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#148
of 216 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TRVI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ProShare Advisors LLC holds $336,334,656 across 174 Biotechnology names. TRVI ranks #75 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
287,847 | $142,982,240 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
119,240 | $74,350,909 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
128,514 | $38,686,569 | |
| 4 | INCY |
Incyte Corp
|
48,152 | $5,458,510 | |
| 5 | MRNA |
Moderna, Inc.
|
70,621 | $4,945,588 | |
| 6 | CYTK |
Cytokinetics Inc
|
27,121 | $2,310,437 | |
| 7 | TECH |
BIO-TECHNE Corp
|
30,597 | $2,161,678 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
4,760 | $1,769,149 |
All Filings in TRVI
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $348,587 | 18,691 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $233,780 | 19,596 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $278,807 | 22,269 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $176,796 | 19,322 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $105,871 | 19,355 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $126,806 | 20,160 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $85,222 | 20,685 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $37,060 | 11,096 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||